133 related articles for article (PubMed ID: 19628080)
1. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
Schwarz RE; Konduri S; Awasthi N; Cafasso D; Schwarz MA
Surgery; 2009 Aug; 146(2):241-9. PubMed ID: 19628080
[TBL] [Abstract][Full Text] [Related]
2. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Biol Ther; 2010 Jul; 10(1):99-107. PubMed ID: 20495354
[TBL] [Abstract][Full Text] [Related]
3. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
5. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
6. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
8. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
Schwarz RE; Schwarz MA
J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
13. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
14. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
15. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI; Grygorenko VN
Exp Oncol; 2011 Dec; 33(4):231-4. PubMed ID: 22217713
[TBL] [Abstract][Full Text] [Related]
16. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
17. Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Kleespies A; Ischenko I; Eichhorn ME; Seeliger H; Amendt C; Mantell O; Jauch KW; Bruns CJ
Clin Cancer Res; 2008 Sep; 14(17):5426-36. PubMed ID: 18765534
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
[TBL] [Abstract][Full Text] [Related]
19. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
20. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]